{"id":22867,"date":"2024-03-29T08:45:45","date_gmt":"2024-03-29T12:45:45","guid":{"rendered":"https:\/\/participatorymedicine.org\/epatients\/?p=22867"},"modified":"2024-03-28T23:10:06","modified_gmt":"2024-03-29T03:10:06","slug":"the-challenge-for-medicare-part-d-patients-inability-to-utilize-pharmaceutical-programs-to-reduce-medication-costs","status":"publish","type":"post","link":"https:\/\/participatorymedicine.org\/epatients\/2024\/03\/the-challenge-for-medicare-part-d-patients-inability-to-utilize-pharmaceutical-programs-to-reduce-medication-costs.html","title":{"rendered":"The Challenge for Medicare Part D Patients: Inability to Utilize Pharmaceutical Programs to Reduce Medication Costs"},"content":{"rendered":"
Guest post by long-time SPM member Tracy Zervakis.<\/strong> Participatory medicine involves professionals and patients working together to get healthcare done. When a treatment plan is agreed and chosen, the best outcome obviously requires carrying out the plan – but both patients and professionals in SPM have found we’re too often blocked by bureaucratic messes like this story. <\/em><\/p>\n Note, it’s an intersection of good intentions by both pharma and government programs, each failing to view the problem from the patient’s perspective and take responsibility for protecting patient vulnerabilities.<\/em><\/p>\n How might we fix this? Let us know in the comments.<\/em><\/p>\n
\n